New trial aims to shield hearts from chemo side effects
NCT ID NCT07572175
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a drug called sotagliflozin can prevent heart, muscle, and fat damage caused by a common type of chemotherapy (anthracycline) in people with newly diagnosed lymphoma. About 60 adults who are scheduled to receive high-dose anthracycline will take either the drug or a placebo during treatment. The goal is to see if the drug helps keep the heart pumping strongly and reduces other side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTHRACYCLINE INDUCED CARDIOTOXICITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- A second chance: new tests aim to catch hidden heart damage in childhood cancer survivors
- Can a PET scan reveal hidden heart harm from lung cancer treatment?
- Can engineered immune cells tackle brain lymphoma?
- Talking about the end: could guided conversations reduce futile cancer treatments?